VYGR - Voyager Therapeutics, Inc.
| Previous Close | 22.15 |
| Open | 22.08 |
| Bid | 20.88 x 800 |
| Ask | 28.62 x 1100 |
| Day's Range | 21.46 - 22.62 |
| 52 Week Range | 7.76 - 25.74 |
| Volume | 320,981 |
| Avg. Volume | 539,980 |
| Market Cap | 805.156M |
| Beta (3Y Monthly) | 2.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.17 |
- GlobeNewswire•17 hours ago
Voyager Therapeutics Announces Management Updates
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah Sah, Ph.D. as Voyager’s chief scientific officer, and the appointment by Voyager of Omar Khwaja, M.D., Ph.D., currently Voyager’s chief medical officer, to the expanded role of chief medical officer and head of research and development. Dr. Sah has agreed to serve as a consultant to Voyager and become a member of its scientific advisory board.
- Zacks•14 days ago
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -2.53% and 73.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•14 days ago
Voyager Therapeutics: 1Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 81 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•14 days ago
Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its first quarter 2019 financial results, program progress and corporate updates. “The first quarter was an eventful period for Voyager as we announced new collaborations, provided updates to our pipeline programs, and advanced our discovery efforts focused on novel gene therapy capsids that have the potential to cross the blood-brain barrier and target specific cells within the brain after a single, systemic administration,” said Andre Turenne, president and chief executive officer of Voyager.
- GlobeNewswire•16 days ago
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson’s disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. Treatment with VY-AADC improved good ON time (ON time without troublesome dyskinesia) by 1.7 hours from baseline and reduced OFF time by 2.2 hours at 12 months from baseline in patients with Parkinson’s disease.
- Zacks•19 days ago
Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•21 days ago
What Are Analysts Expecting From Voyager Therapeutics, Inc. (NASDAQ:VYGR) Over The Next Few Years?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings announcement Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) released in December...
- GlobeNewswire•22 days ago
Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) taking place April 29-May 2, 2019, in Washington, D.C. New preclinical data at this year’s ASGCT relate to Voyager’s vectorized antibody program directed against tau for the potential treatment of Alzheimer’s disease, its new TRACER™ system to discover adeno-associated virus (AAV) capsids with blood-brain barrier crossing and cell-specific transduction properties, as well as VY-SOD102 targeting a monogenic form of Amyotrophic Lateral Sclerosis (ALS) called SOD1. “One of the major limitations of biologic therapies for the treatment of severe neurodegenerative diseases is the ability of those therapies to cross the blood-brain barrier,” said Dinah Sah, Ph.D., chief scientific officer of Voyager.
- GlobeNewswire•last month
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
CAMBRIDGE, Mass., April 15, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
- GlobeNewswire•2 months ago
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert Hesslein as inducements material to his entering an employment agreement with Voyager to serve as its general counsel. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4) and became effective upon the commencement of Mr. Hesslein’s employment on April 1, 2019. Mr. Hesslein received a restricted stock unit award for 28,125 shares of Voyager common stock and a non-qualified stock option to purchase 168,750 shares of Voyager common stock.
- GlobeNewswire•2 months ago
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass., April 02, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
- GlobeNewswire•2 months ago
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in the peer-reviewed journal, Annals of Neurology. The publication titled “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease,” can be accessed online.
- GlobeNewswire•2 months ago
MRI Interventions Announces Collaboration with Voyager Therapeutics for the Design, Manufacture and Supply of V-TAG™ Device
MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager. Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.
- Investopedia•2 months ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- ACCESSWIRE•2 months ago
Rare Disease Therapies Draw Big Biopharma's Interest
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
- GlobeNewswire•2 months ago
Consolidated Research: 2019 Summary Expectations for AMC Entertainment, Spirit Airlines, Voyager Therapeutics, CIT Group, Kaman, and CommVault — Fundamental Analysis, Key Performance Indications
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•3 months ago
Here's Why Voyager Therapeutics Stock Rose as Much as 13% Today
The gene therapy company saw another peer get gobbled up in an acquisition.
- Barrons.com•3 months ago
Why Big Pharma Is Diving Into Gene Therapy
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VYGR earnings conference call or presentation 26-Feb-19 9:30pm GMT
Q4 2018 Voyager Therapeutics Inc Earnings Call
Motley Fool•3 months agoVoyager Therapeutics, Inc. (VYGR) Q4 2018 Earnings Conference Call Transcript
VYGR earnings call for the period ending December 31, 2018.
- GlobeNewswire•3 months ago
Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced.
- Zacks•3 months ago
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
- ACCESSWIRE•3 months ago
Watch These Four Biotech Stocks Friday
CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need of care. Naturally, companies in the biotech sector working to address these challenges are garnering significant notoriety among consumers as well as investors. Premier Health Group (PHGRF) (PHGI), Ocular Therapeutix Inc (OCUL), Voyager Therapeutics Inc (VYGR), and Amarin Corporation plc (NASDAQ:AMRN) represent 4 biotech stocks stepping up their game on Friday.
- Motley Fool•3 months ago
Why Voyager Therapeutics Is Skyrocketing Today
The small biotech stock soared thanks to a big deal with a big pharma company.
- American City Business Journals•3 months ago
Voyager Therapeutics stock jumps on 2nd Parkinson's deal
Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (Nasdaq: ABBV), launching a research effort to develop antibody treatments that can be delivered directly to the brain and target a protein called alpha-synuclein.
